Back to top
more

McKesson (MCK)

(Real Time Quote from BATS)

$595.59 USD

595.59
432,346

+5.60 (0.95%)

Updated Jul 25, 2024 03:55 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Catalent (CTLT) Stock Down Despite Q4 Beat: Will it Recover?

by Zacks Equity Research

Catalent's (CTLT) fiscal fourth-quarter earnings beat but the stock falls 7.4% following the earnings release on Aug 29. Here we discuss the factors that are set to guide its share price going forward.

Here's Why You Should Hold on to Nevro (NVRO) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO), owing to its strength in the global SCS market.

Teladoc Health (TDOC) Ties Up to Upgrade RPM Care in Canada

by Zacks Equity Research

Teladoc Health (TDOC) teams up with Cloud DX to bring its virtual care capabilities to the latter's platform and dispense advanced RPM solutions to the Canadian residents.

Myriad Genetics (MYGN) Gets Extensive Coverage for BRACAnalysis

by Zacks Equity Research

Myriad Genetics' (MYGN) BRACAnalysis gained expanded coverage from MHLW to identify breast cancer patients who are eligible for treatment with Lynparza in Japan.

Here's Why You Should Retain Inari Medical (NARI) Stock Now

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.

What's in Store for Patterson Companies (PDCO) in Q1 Earnings?

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect an improvement at the Animal Health segment.

Catalent (CTLT) Q4 Earnings Beat Estimates, Revenues Lag

by Zacks Equity Research

Catalent's (CTLT) robust performance across most of its segments drives its fourth-quarter fiscal 2022 top line.

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

Here's Why Investors Should Retain Myriad Genetics (MYGN) Now

by Zacks Equity Research

Investors are optimistic about Myriad Genetics' (MYGN) better-than-expected results and strong testing volumes.

Is McKesson (MCK) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Veeva Systems (VEEV) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Veeva Systems' (VEEV) Q2 earnings are likely to have been driven by strength in its commercial business.

Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio

by Zacks Equity Research

Veeva Systems' (VEEV) slew of strategic deals raises optimism about the stock.

Fresenius Medical (FMS) Robust Product Portfolio Drives Growth

by Zacks Equity Research

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Catalent (CTLT) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Catalent's (CTLT) Q4 results are likely to have been driven by robust segmental performances.

3 Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio

by Zacks Equity Research

Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.

Phibro (PAHC) Q4 Earnings Miss Estimates, Sales Surpass

by Zacks Equity Research

Phibro (PAHC) posts better-than-expected revenues for the fiscal fourth quarter, with robust growth across all segments.

3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio Now

by Zacks Equity Research

Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

Abbott (ABT) to Offer New Treatment Option for Chronic Pain

by Zacks Equity Research

Abbott's (ABT) Proclaim Plus SCS system with FlexBurst360 therapy will cater to the changing needs of patients with chronic pain.

Here's Why You Should Retain Exact Sciences (EXAS) Now

by Zacks Equity Research

Investors are optimistic about Exact Sciences' (EXAS) better-than-expected results and robust Cologuard volumes.

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Medtronic (MDT) Q1 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Medtronic (MDT) posts better-than-expected results for the fiscal first quarter and maintains earnings and sales outlook for the full year.

3 Reasons to Hold OPKO Health (OPK) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee.

Here's Why You Should Buy McKesson (MCK) Stock Right Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Here's How Much You'd Have If You Invested $1000 in McKesson a Decade Ago

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Here's Why You Should Invest in Bio-Rad (BIO) Stock Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad's (BIO) better-than-expected results and continued growth across major geographies.